Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

PHASE4CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

October 31, 2001

Study Completion Date

June 30, 2003

Conditions
Raynaud's Disease
Interventions
DRUG

Pletal

Trial Locations (18)

10595

New York Medical College, Valhalla

11040

Schneider Children's Hospital, New Hyde Park

11203

SUNY Downstate Medical Center, Brooklyn

14222

Children's Hospital of Buffalo, Buffalo

17033

The Milton S. Hershey Medical Center, Hershey

23510

Monarch Research Associates, Norfolk

29425

Medical University of South Carolina, Charleston

43606

Jobst Vascular Center, Toledo

60649

LaRabida Children's Hospital, Chicago

63104

St. Louis University Health Sciences Center, St Louis

68114

Children's Hospital, Omaha

93637

Madera Family Medical Group, Madera

93710

Advanced Medical Research Institute, Fresno

98105

Children's Hospital and Regional Medical Center, Seattle

99508

Advanced Medical Clinical Therapeutics, Anchorage

06106

Connecticut Children's Medical Center, Hartford

02115

Children's Hospital Boston, Boston

07103

Asthma & Allergy Research Center, Newark

Sponsors
All Listed Sponsors
lead

Otsuka America Pharmaceutical

INDUSTRY

NCT00048763 - Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon | Biotech Hunter | Biotech Hunter